Arbutus Biopharma Analyst Ratings
BenzingaMay 3 09:19 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
TipRanksMay 3 07:11 ET
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
TipRanksMay 3 00:30 ET
Arbutus Biopharma Analyst Ratings
BenzingaApr 4 08:43 ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
TipRanksApr 3 15:20 ET
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
TipRanksMar 5 01:23 ET
Arbutus Biopharma Analyst Ratings
BenzingaMar 1 07:21 ET
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
TipRanksFeb 29 13:55 ET
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
TipRanksJan 29 16:35 ET
Arbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospects
TipRanksJan 9 20:55 ET
Promising Phase IIa Trial Results Bolster Buy Rating for Arbutus Biopharma: An Analysis of VTP-300's Potential and Future Trials
TipRanksNov 12, 2023 23:35 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arbutus Biopharma (ABUS) and Bluebird Bio (BLUE)
TipRanksNov 10, 2023 06:01 ET
Promising Developments in HBV Treatment: A Comprehensive Analysis of Arbutus Biopharma's AB-729-202 Phase 2a Study and Buy Rating Justification
TipRanksNov 8, 2023 06:42 ET
Arbutus Biopharma Earns Buy Rating: Strong Financial Position, Workforce Changes, and Promising Hepatitis B Treatment Developments
TipRanksNov 7, 2023 13:45 ET
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating
MT NewswiresSep 12, 2023 08:28 ET
Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF) and Arbutus Biopharma (ABUS)
TipRanksSep 12, 2023 07:00 ET
Arbutus Biopharma Analyst Ratings
BenzingaSep 12, 2023 06:26 ET
H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
TipRanksSep 12, 2023 06:15 ET
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS)
TipRanksSep 11, 2023 22:25 ET
Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)
TipRanksAug 8, 2023 05:15 ET
No Data
No Data